Newsfeeds Archive - Spark Newswire

2 minute read

Citius Pharma’s ‘Antibiotic Lock’ Effective In Patients With Catheter-Associated Bloodstream Infections

May 21, 1:40 PM

Citius Pharmaceuticals' Phase 3 trial results for Mino-Lok, an antibiotic lock solution for central line-associated infections, show significant improvement in time to catheter failure and overall treatment success.

CTXR

1 minute read

Movers

12 Health Care Stocks Moving In Tuesday’s Pre-Market Session

By Benzinga Insights

May 21, 8:06 AM

Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares increased by 67.7% to $2.13 during Tuesday’s pre-market session. The market value of…

AKAN

1 minute read

Movers

12 Health Care Stocks Moving In Thursday’s Pre-Market Session

By Benzinga Insights

April 18, 8:09 AM

Gainers Bio-Path Hldgs (NASDAQ:BPTH) shares increased by 43.8% to $4.66 during Thursday’s pre-market session. The market value of…

BNTC

3 minute read

Citius Pharmaceuticals Completes Enrollment In Pivotal Phase 3 Trial Of Its Mino-Lok Therapeutic To Salvage Catheters; Topline Results Expected 2Q 2024

By Benzinga Newsdesk

January 2, 9:37 AM

Topline results expected 2Q 2024Study enrolled a total of 241 patients; 109 catheter failures observedFirst-and-only antibiotic lock solution in development to salvage catheters in patients with CRBSICRANFORD, N.J., Jan.

CTXR

4 minute read

Citius Pharmaceuticals Announces Publication In Frontiers Of Immunology Of Results From Solid Tumor Study Of LYMPHIR In Combination With Checkpoint Inhibitor

By Benzinga Newsdesk

October 31, 8:47 AM

Preclinical study demonstrates that adding LYMPHIR to anti-PD-1 treatment augments anti-tumor activity and improves overall survival compared to monotherapy alone by transiently depleting Tregs in the tumor

CTXR

1 minute read

Movers

12 Health Care Stocks Moving In Tuesday’s Pre-Market Session

By Benzinga Insights

October 24, 9:06 AM

Gainers LianBio (NASDAQ:LIAN) stock increased by 79.8% to $2.5 during Tuesday’s pre-market session. The market value of their…

CTXR

25 minute read

Options

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

September 26, 12:04 PM

On Tuesday, 386 stocks made new 52-week lows.

$TKO

2 minute read

Citius Pharmaceuticals, Inc. Receives Regulatory Guidance From The FDA Regarding The Planned Resubmission Of The BLA For LYMPHIR; Resubmission To FDA Planned For Early 2024

By Benzinga Newsdesk

September 8, 8:02 AM

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR) is pleased to announce the Company has received additional guidance from the U.S. Food and Drug Administration (FDA) regarding the planned

CTXR

2 minute read

Citius Pharmaceuticals Reaches 92 Event Milestone In Mino-Lok Phase 3 Trial

By Benzinga Newsdesk

August 10, 8:44 AM

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced

CTXR

4 minute read

Why Apellis Pharmaceuticals Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Monday’s Session

By Lisa Levin

July 31, 3:30 PM

Gainers Yellow Corporation (NASDAQ: YELL) shares jumped 106% to $1.46. The trucking company ceased operations on Sunday, according to a Wall Street Journal report.

ACAX